3 completed, 1 recruiting. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Aelis Farma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AEF0217 in Participants With Down Syndrome AEF0217 100 µg, AEF0217 300 µg, Placebo - Down Syndrome (Trisomy 21) | Phase 2 | Recruiting | Aelis Farma | 188 | 2025-12-22 | 2026-04-08 |
| Phase 1/2 Trial of AEF0217 in Participants With Down Syndrome Placebo, AEF0217 - Down Syndrome | Phase 1 / Phase 2 | Completed | Aelis Farma | 40 | 2022-12-15 | 2024-10-10 |
| Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD) AEF0117, Placebo oral capsule - Marijuana Abuse | Phase 2 | Completed | Aelis Farma | 333 | 2022-05-06 | 2024-07-30 |
| Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects AEF0117, Placebo oral capsule - Marijuana Abuse | Phase 2 | Completed | Aelis Farma | 29 | 2018-10-23 | 2021-06-02 |
Down Syndrome (2) · Marijuana Abuse (2) · Cognitive Dysfunction (1)
Spain (2) · United States (2) · France (1) · Italy (1)
Frances Levin, MD (1) · Haig Goenjian, MD (1) · Jennifer Potter, MD (1) · Jennifer Wisdom, MD (1) · Kevin Gray, MD (1) · Larissa Mooney, MD (1) · Margareth Haney, PhD (1) · Matt Evans, MD (1) · Olga Lapeyra, MD (1) · Paul Thielking, MD (1) · Rajita Sinha, MD (1) · Richi Kakar, MD (1)
2025 (1), R01DA038875 (1)